Suppr超能文献

良性多发性硬化的定义、患病率及预测因素

Definition, prevalence and predictive factors of benign multiple sclerosis.

作者信息

Reynders Tatjana, D'haeseleer Miguel, De Keyser Jacques, Nagels Guy, D'hooghe Marie B

机构信息

Department of Neurology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, Jette 1090, Belgium.

Center for Neurosciences, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, Belgium.

出版信息

eNeurologicalSci. 2017 May 13;7:37-43. doi: 10.1016/j.ensci.2017.05.002. eCollection 2017 Jun.

Abstract

BACKGROUND

Multiple sclerosis (MS) is characterized by a great inter-individual variability in disease course and severity. Some patients experience a rather mild course, controversially called 'benign MS' (BMS). The usefulness of this entity in clinical practice remains unclear.

METHODS

We performed a literature search in PubMed, Web of Science and Cochrane Library databases from November 1980 to December 2015, using the following key words: , , , , , and predefined inclusion criteria.

RESULTS

Our search yielded 26 publications. Most definitions were based on the Expanded Disease Status Scale (EDSS), which is heavily weighted towards physical disability. Between 30 and 80% of relapsing-remitting MS patients have EDSS < 3 or 4 at 10 years after onset. Having only one relapse in the first 5 years and EDSS ≤ 2 at 5 years or EDSS ≤ 3 at 10 years appears to be predictive for a prolonged benign disease course, without protecting against disease progression at a later stage. Evidence on the predictive value of MRI parameters remains limited.

CONCLUSIONS

Current BMS definitions have some predictive value for future physical disability, but do not take into account the age at EDSS and the potentially disrupting effects of non-EDSS symptoms and cognitive impairment. It appears to correspond to mild RRMS in the first decades and its prevalence varies. Since early and accurate prediction of BMS is not yet possible, the clinical relevance is limited. Research approaches are suggested.

摘要

背景

多发性硬化症(MS)的特点是个体间疾病进程和严重程度差异很大。一些患者经历的病程较为轻微,有争议地被称为“良性MS”(BMS)。该实体在临床实践中的实用性仍不明确。

方法

我们于1980年11月至2015年12月在PubMed、科学网和考克兰图书馆数据库中进行文献检索,使用以下关键词: 、 、 、 、 、 以及预定义的纳入标准。

结果

我们的检索得到26篇出版物。大多数定义基于扩展疾病状态量表(EDSS),该量表严重偏向身体残疾情况。30%至80%的复发缓解型MS患者在发病10年后EDSS评分<3或4。在最初5年内仅复发一次且5年时EDSS≤2或10年时EDSS≤3似乎可预测疾病良性病程延长,但不能预防后期疾病进展。关于MRI参数预测价值的证据仍然有限。

结论

当前的BMS定义对未来身体残疾有一定预测价值,但未考虑EDSS评分时的年龄以及非EDSS症状和认知障碍的潜在干扰影响。它似乎在最初几十年对应轻度复发缓解型MS,其患病率各不相同。由于目前尚无法早期准确预测BMS,其临床相关性有限。本文提出了研究方法。

相似文献

1
Definition, prevalence and predictive factors of benign multiple sclerosis.
eNeurologicalSci. 2017 May 13;7:37-43. doi: 10.1016/j.ensci.2017.05.002. eCollection 2017 Jun.
2
Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.
Acta Neurol Scand. 2016 Mar;133(3):183-91. doi: 10.1111/ane.12442. Epub 2015 May 26.
3
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration.
Mult Scler Relat Disord. 2020 Nov;46:102485. doi: 10.1016/j.msard.2020.102485. Epub 2020 Sep 3.
4
Mitoxantrone: a review of its use in multiple sclerosis.
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
5
Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
Mult Scler Relat Disord. 2022 Jan;57:103353. doi: 10.1016/j.msard.2021.103353. Epub 2021 Oct 29.
7
Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Neurology. 2007 Feb 13;68(7):496-500. doi: 10.1212/01.wnl.0000253185.03943.66.
8
Rituximab for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
10
Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Eur J Neurol. 2007 Aug;14(8):885-9. doi: 10.1111/j.1468-1331.2007.01810.x.

引用本文的文献

2
Beyond the Stroke: A Case Report of Multiple Sclerosis.
Cureus. 2024 Nov 18;16(11):e73962. doi: 10.7759/cureus.73962. eCollection 2024 Nov.
3
Dynamic 18 F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study.
Neurol Sci. 2025 Apr;46(4):1783-1787. doi: 10.1007/s10072-024-07921-x. Epub 2024 Dec 18.
4
Building digital patient pathways for the management and treatment of multiple sclerosis.
Front Immunol. 2024 Feb 15;15:1356436. doi: 10.3389/fimmu.2024.1356436. eCollection 2024.
5
Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis.
Heliyon. 2024 Feb 17;10(4):e26658. doi: 10.1016/j.heliyon.2024.e26658. eCollection 2024 Feb 29.
6
Cerebellar pathology in multiple sclerosis and experimental autoimmune encephalomyelitis: current status and future directions.
J Cent Nerv Syst Dis. 2023 Nov 6;15:11795735231211508. doi: 10.1177/11795735231211508. eCollection 2023.
7
Performance of administrative databases for identifying individuals with multiple sclerosis.
Sci Rep. 2023 Oct 25;13(1):18310. doi: 10.1038/s41598-023-45384-w.
8
Rest-Activity Rhythm, Pain, and Motor Activity in Multiple Sclerosis.
Int J MS Care. 2023 Jul-Aug;25(4):157-162. doi: 10.7224/1537-2073.2021-030. Epub 2023 Mar 8.
9
Multiple sclerosis and lower urinary tract symptoms: A survey of prevalence, characteristic and urological evaluations.
SAGE Open Med. 2023 Jun 25;11:20503121231178047. doi: 10.1177/20503121231178047. eCollection 2023.
10
The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis - A Single Centre's Experience.
CNS Neurol Disord Drug Targets. 2024;23(6):791-799. doi: 10.2174/1871527322666230609164534.

本文引用的文献

1
Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
Mult Scler. 2017 Dec;23(14):1938-1946. doi: 10.1177/1352458517690618. Epub 2017 Feb 3.
2
Clinical course of multiple sclerosis: A nationwide cohort study.
Mult Scler. 2017 Oct;23(11):1488-1495. doi: 10.1177/1352458516681197. Epub 2016 Dec 12.
3
Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.
Nat Rev Neurol. 2017 Jan;13(1):25-36. doi: 10.1038/nrneurol.2016.187. Epub 2016 Dec 9.
4
Long-term evolution of multiple sclerosis disability in the treatment era.
Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.
5
No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
Mult Scler. 2016 Jan;22(1):64-72. doi: 10.1177/1352458515604383. Epub 2015 Oct 2.
6
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21.
7
Health-related quality of life in patients with longstanding 'benign multiple sclerosis'.
Mult Scler Relat Disord. 2015 Jan;4(1):31-8. doi: 10.1016/j.msard.2014.09.211. Epub 2014 Oct 7.
8
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.
J Neurol. 2015 May;262(5):1148-63. doi: 10.1007/s00415-015-7674-y. Epub 2015 Feb 26.
9
Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare.
J Family Med Prim Care. 2013 Jan;2(1):9-14. doi: 10.4103/2249-4863.109934.
10
Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75. doi: 10.1136/jnnp-2012-304333. Epub 2013 Mar 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验